Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients

BACKGROUND: The clinical significance of programmed cell death protein-1 (PD-1)-targeted immunotherapy in Chinese patients is understudied. We thus aimed to evaluate the safety and efficacy of PD-1 inhibitors with toripalimab, camrelizumab or sintilimab for Chinese hepatocellular carcinoma (HCC) pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jinzhang, Hu, Xiaoyun, Li, Qi, Dai, Wencong, Cheng, Xiao, Huang, Wei, Yu, Wenxuan, Chen, Mian, Guo, Yabing, Yuan, Guosheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576044/
https://www.ncbi.nlm.nih.gov/pubmed/33241036
http://dx.doi.org/10.21037/atm-20-6063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576044/
https://www.ncbi.nlm.nih.gov/pubmed/33241036
http://dx.doi.org/10.21037/atm-20-6063

Ejemplares similares